secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001062993-25-013468
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus Pharma signs non-binding MoU with HelixNano for thermostable mRNA vaccine development
--------------------------------------------------------------------------------

- Non-binding MoU to combine Medicus' MNA delivery platform with HelixNano's mRNA platform for thermostable infectious disease vaccines.
- Parties aim to form a joint venture for co-development and commercialization of thermostable mRNA-based vaccines.
- Plan a Phase 1 bridging study comparing IM injection vs. intradermal MNA delivery of HelixNano's vaccine candidate HN-0001.
- Preliminary activities include a Sponsored Research Agreement with University of Pittsburgh (Dr. Lou Falo), supply of HN-0001, and loading into Medicus' MNAs.
- MoU is non-binding; no obligation to proceed with joint venture until definitive agreements are executed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325013468/0001062993-25-013468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325013468/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-25-013468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer